Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Jul 2020 13:31

RNS Number : 0578U
Midatech Pharma PLC
24 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Midatech Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

SPREADEX LTD

City and country of registered office (if applicable)

St Albans, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

21/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

24/07/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Less than 3%

39,252,557

Position of previous notification (if

applicable)

3.82%

0.52%

4.34%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

SUBTOTAL 8. A

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

David Corben

01727895193

 

Place of completion

UK

Date of completion

24/07/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLRIMTTMTTTBLM
Date   Source Headline
20th Dec 20177:00 amRNSMidatech initiates Gelclair Phase IV trial
22nd Nov 20177:00 amRNSMidatech receives manufacturing certification
7th Nov 20179:35 amRNSIssue of Equity for Midatech Share Incentive Plan
19th Oct 201710:52 amRNSHolding(s) in Company
19th Oct 20179:44 amRNSHoldings in Company
16th Oct 201712:44 pmRNSResult of General Meeting
28th Sep 20172:35 pmRNSResult of Placing to raise £6m & PDMR Shareholding
28th Sep 20177:01 amRNSInterim Results 2017
28th Sep 20177:00 amRNSProposed Placing and Open Offer
21st Sep 20179:00 amRNSHolding(s) in Company
7th Sep 20177:00 amRNSNotice of interim results
4th Sep 20177:00 amRNSMidatech submits MTD201 CTA filing
25th Aug 20171:59 pmRNSHolding(s) in Company
26th Jul 20177:00 amRNSCompletion of pre-clinical liver cancer programme
18th Jul 20177:00 amRNSTrading Update and Notice of Results
13th Jun 20177:00 amRNSSite visit for investors and analysts
7th Jun 20177:00 amRNSMidatech signs global agreement for panobinostat
22nd May 20177:00 amRNSProgress update on brain cancer therapies
19th May 20173:12 pmRNSIssue of Equity for Midatech Share Incentive Plan
3rd May 20172:30 pmRNSResult of AGM
4th Apr 20177:02 amRNSFinancial results for year ended 31 December 2016
14th Mar 20177:00 amRNSNotice of Results
10th Mar 20177:00 amRNSMidatech Announces Initial Scale-Up of Facility
27th Feb 20177:00 amRNSMidatech enters into Loan Agreement with SVB
20th Jan 201711:05 amRNSSecond Price Monitoring Extn
20th Jan 201711:00 amRNSPrice Monitoring Extension
20th Jan 20177:00 amRNSTrading Update
20th Dec 201612:56 pmRNSDirector/PDMR Shareholding
15th Dec 20164:31 pmRNSHolding(s) in Company
22nd Nov 20167:00 amRNSMidatech receives upfront on Emergex vaccine deal
15th Nov 20167:00 amRNSMidatech selects MTR104 for liver cancer treatment
2nd Nov 201612:57 pmRNSHolding(s) in Company
2nd Nov 20169:51 amRNSHolding(s) in Company
28th Oct 201611:12 amRNSResult of GM, Open Offer & Issue of Equity
11th Oct 20162:59 pmRNSResults of Placing to raise £16.0 million
11th Oct 201611:18 amRNSProposed Placing and Open Offer
30th Sep 20167:00 amRNSFirst in Human Immunotherapy Study Start
21st Sep 20167:00 amRNSMidatech Pharma US Partnership with R-Pharm US
2nd Sep 20167:00 amRNSInterim Results
10th Aug 20167:00 amRNSTrading Update and Notice of Results
7th Jul 20168:15 amRNSMidatech receives grant funding
30th Jun 20161:11 pmRNSAnnual Report Posting
27th Jun 20167:00 amRNSIssue of Equity and Director's Dealings
18th May 20167:00 amRNSMidatech Pharma announces clinical pipeline update
11th May 20165:28 pmRNSResult of AGM
11th May 20167:00 amRNSAGM Statement and Update on Trading
26th Apr 20167:00 amRNSMidatech announces positive Q-Octreotide data
21st Apr 20167:00 amRNSPositive data for OpsiSporin Uveitis programme
13th Apr 20167:00 amRNSFinancial results for the year ended 31 Dec 2015
11th Apr 20167:00 amRNSCommercial Launch of Zuplenz® (Ondansetron) in US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.